Development and evaluation of controlled-release buccoadhesive verapamil hydrochloride tablets

Daru

Volumn 16, Issue 2, 2008, Pages 60-69

  Emami, J ^a   Varshosaz, J ^a   Saljoughian, N ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Buccoadhesive tablets; Controlled release; Verapamil hydrochloride

Indexed keywords

CARBOMER; CARBOXYMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; VERAPAMIL;

ARTICLE; CONTROLLED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; TABLET COMPRESSION; TABLET HARDNESS; TABLET THICKNESS;

EID: 45849108814     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Clin Pharmacokinet 1998; 34:457-482.
2. Reynolds JEF. Martindale, The Extra Pharmacopoeia, Vol. 33, The Royal Pharmaceutical Society, Great Britain, London 2002; 989-991.
3. Buzinkaiova T, Skacani I, Netriova J. Quantitative assay of verapamil in drugs and serum by capillary isotachophoresis. Pharmazie, 1995; 50:799-800.
4. Clarke EG. Isolation and identification of drugs, London, The pharmaceutical press. 2004; 1695-1697.
5. Jankowski A, Marzec A, Lamparczyk H. Comparative bioavailability of verapamil from rapidly absorbed and slow release preparations. J Pharm Biomed Anal 1991; 10:1101-1103.
6. Harder S, Thurmann P, Siewert M, Blume H, Huber TH, Rietbrock N. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and controlled release formulation. J Cardiovasc Pharmacol 1991; 17:207-212.
7. Elkheshen SA. Bioadhesive matrix as controlled release dosage form for verapamil hydrochloride. Pharm Ind 1998; 60:555-559.
8. Ahmed JH, Merdith PA, Ellott HL. The influence of age on the pharmacokinetics of verapamil. Pharmacol Res 1991; 24 (3):227-233.
9. Longer MA, Ch'ng HS, Robinson JR. Bioadhesive polymers as platform for oral controlled drug delivery. J Pharm Sci 1985; 74:406-411.
10. Smith DHG. Pharmacology of cardiovascular chronotherapeutic agents. Am J Hypertens 2001; 14:2965-3015.
11. Pfizer Canada Inc. Submission Control No: 106194. Product monograph.
12. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled-release osmotic delivery system (OROS), an advanced oral delivery form. Current Medical Research and Opinion, 2006; 22 (10):1879-1892.
13. Elkheshen S, Yassin AE, Alkhaled, F. Per-oral extended release bioadhesive tablet formulation of verapamil HCL. Bolletino Chimico Farmaceutico 2003; 142 (5):226-231.
14. Siahi MR, Barzegar-Jalali M, Monnajemzadeh F, Ghaffari F, Azarmi S. Design and evaluation of 1-and 3 layer matrices of verapamil HCL for sustaining its release. AAPS PharmSciTech, 2005; 6(4):626-632.
15. El-Gazayerly ON, Rakkanka V, Ayres JW. Novel chewable sustained-release tablet containing verapamil hydrochloride. Pharm Dev Tech 2004; 9(2):181-8.
16. Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation of pH-independent sustained-release matrix tablets of verapamil HCl using directly compressible Eudragits Pharm Dev Tech 2003, 8(4):323-33.
17. Mukherjee B, Mahanti B, Panda P, Mahanpatra S. Preparation and evaluation of verapamil hydrochloride microcapsules. Am J of Ther 2005; 12(5):417-424.
18. Govindarajan R, Nagarsenker MS. Basic drug-enterosoluble polymer co-evaporates: development of oral controlled release systems. Drug Dev Ind Pharm 2004; 30(8):847-857.
19. Chen GL, Hao WH. In vitro performance of floating sustained-release capsule of verapamil. Drug Dev Ind Pharm 1998; 24(11):1067-1072.
20. Sawicki W, Glod J. Preparation of floating pellets with verapamil hydrochloride. Acta Poloniae Pharmaceutica 2004; 61(3):185-90, 2004.
21. Dashevsky A, Kolter K, Bodmeier R. pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat SR 30 D and the enteric polymer dispersion Kollicoat MAE 30 DP. Eur J Pharm Biopharm 2004; 58(1):45-9.
22. Kusum Devi V, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm 2003, 29(5):495-503.
23. Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J 1996; 132(6):1202-6.
24. Passerini N, Perissutti B, Albertini B, Voinovich D, Moneghini M, Rodriguez L. Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing. J Control Release 2003; 88(2):263-75.
25. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliver Rev 2005; 57:1666-1691.
26. Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery- A promising option for orally less efficient drugs. J Control Release 2006; 114:15-40.
27. Shojaeei AH. Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Pharmaceut Sci 1998; 1(1):15-30.
28. Burgalassi S, Panichi L, Saettone MF, Jacobsen J, Rassing MR. Development and in vitro/ in vivo testing of mucoadhesive buccal patches releasing benzylamine and lidocaine. Int J Pharm 1996; 133:1-7
29. Remunan-lopez C, Portero A, Vila-jato JL, Alonso MJ. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered device for buccal drug delivery. J Control release 1998; 55:143-152.
30. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1997; 23:489-515.
31. Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M. Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. Eur J Pharm Biopharm 2002; 53:233-239.
32. Martin L, Wilson CG, Koosha F, Uchegbu IF. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. Eur J Pharm Biopharm 2003; 55:35-45.
33. Park CR, Munday DL. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int J Pharm 2002; 237:215-226.
34. Minghetti P, Colombo A, Montanari L, Gaeta GM., Gombos F. Buccoadhesive slow-release tablets of acitretin: Design and 'in vivo' evaluation. Int J Pharm 1998; 169(2):195-202.
35. Llabot JM, Manzo RH, Allemandi DA. Double layered mucoadhesive tablets containing nystatin. AAPS PharmSciTech. 2002; 3(3):E22.
36. th Ed. The United States Pharmacopeial Convention Rockville, MD, prepared by the council of experts and published by the Board of Trustee printed in Canada by Webcom Limited. Toronto, 2005; 2246-2249.
37. Desai KGH, Kumar TMP. Preparation and evaluation of a novel buccal adhesive system. AAPS PharmSciTech 2004; 5 (3): Article 35.
38. Varshosaz J, Dehghan, Z. Development and characterization of buccoadhesive nifedipine tablets. Eur J Pharm Biopharm 2002; 54:135-141.
39. Parodi B, Russo E, Caviglioli G, Cafaggi S, Bigbardi G. Development and characterization of a buccoadhesive dosage form of oxycodane hydrochloride. Drug Dev Ind Pharm 1996; 22 (5):445-450.
40. Agarwal V, Mishra B. Design, development, and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug Dev Ind Pharm 1999; 25 (6):701-709.
41. Peppas NA. Analysis of Fickian and Non-Fickian drug release from polymers. Pharm Actahelv 1985; 60(4):110-112.
42. Dortung B, Ozer L, Uyanik N. Development and In Vitro evaluation of a buccoadhesive pindalol tablet formulation. Drug Dev Ind Pharm 1998; 24 (3):281-288.
43. Anlar S, Capan Y, Guven O, Gogus A, Dalkara T, Hincal A. Formulation and In vitro-In vivo evaluation of buccoadhesive morphine sulfate tablets. Pharm Res 1994; 11(2):231-236.
44. Gupta A, Garg S, Khar RK. Interpolymer complexation and its effect on bioadhesive strength and dissolution characteristics of buccal drug delivery systems. Drug Dev Ind Pharm 1994; 20 (3):315-325.
45. Anlar S, Capan Y, Hincal AA. Physico-chemical and bioadhesive properties of polyacrylic acid polymers. Pharmazie, 1993; 48:285-289.
46. Perioli L, Ambrogi V, Rubini D, Giovagnoli S, Ricci M, Blasi P, Rossi C. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J Control Release 2004; 95:521-533.
47. th Ed. 2003; P 98.
48. Mortazavi SA, Aboofazeli R. Preparation and in vitro assessment of various mucosa-adhesive films for buccal delivery. Daru 2000; 8(1):9-17.